Docoh
Loading...

106 results

Filter options loading...
Top filers
Top filing types
Recent filing years
424B5
PCSA Processa Pharmaceuticals Inc
20 Aug 21
Prospectus supplement for primary offering
4:46pm
as it now exists or may hereafter be amended, against all expense, liability and loss (including attorneys’ fees, judgments, fines, Employee Retirement … limitations. We carry directors’ and officers’ insurance protecting us, any director, officer, employee or agent of ours or who was serving at the request
8-K
EX-1.1
PCSA Processa Pharmaceuticals Inc
20 Aug 21
Entry into a Material Definitive Agreement
4:30pm
with all presently applicable provisions of the Employee Retirement Income Security Act of 1974, as amended, including the regulations and published … , any director, officer, agent, employee or other person associated with or acting on behalf of the Company, (i) has used any corporate funds for any
10-Q
2021 Q2
PCSA Processa Pharmaceuticals Inc
12 Aug 21
Quarterly report
4:01pm
consisted of the following: Stock Based Compensation Awards Employee and Director stock-based compensation Stock-based compensation paid to consultants … of Shares Awarded Number of Shares Vested Restricted stock awards – employee Restricted stock units – employees Restricted stock units – consultants Stock
S-3
PCSA Processa Pharmaceuticals Inc
30 Jun 21
Shelf registration
4:02pm
, liability and loss (including attorneys’ fees, judgments, fines, Employee Retirement Income Security Act excise taxes or penalties and amounts paid … director, officer, employee or agent of ours or who was serving at the request of the Company as a director, officer, employee or agent of another
8-K
EX-10.1
PCSA Processa Pharmaceuticals Inc
17 Jun 21
PROCESSA PHARMACEUTICALS ENTERS INTO A LICENSING AGREEMENT WITH OCUPHIRE PHARMA, INC., FOR the Development of RX-3117
11:35am
such matter to a jointly selected Third Party with expertise in the pricing of pharmaceutical products that is not an employee, consultant, legal … , offer, pay, promise to pay or authorize the giving of money or anything of value to any official or employee of any government or any department
10-Q
2021 Q1
PCSA Processa Pharmaceuticals Inc
13 May 21
Quarterly report
4:30pm
to, payroll costs, mortgage interest, rent or utility costs, and on the maintenance of employee and compensation levels during a certain time period … intangible asset used in research and development activities, and (iv) internal research and development staff related payroll, taxes and employee
DEF 14A
PCSA Processa Pharmaceuticals Inc
22 Apr 21
Definitive proxy
2:00pm
such determinations, our Board of Directors considered the relationships that each such non-employee director has with the Company and all other facts … and circumstances our Board of Directors deemed relevant in determining independence, including the beneficial ownership of our capital stock by each non-employee
424B3
PCSA Processa Pharmaceuticals Inc
12 Apr 21
Prospectus supplement
1:44pm
, against all expense, liability and loss (including attorneys’ fees, judgments, fines, Employee Retirement Income Security Act excise taxes or penalties … ’ insurance protecting us, any director, officer, employee or agent of ours or who was serving at the request of the Company as a director, officer, employee
10-K/A
2020 FY
PCSA Processa Pharmaceuticals Inc
7 Apr 21
Annual report (amended)
4:23pm
Chief Administrative Officer Patrick Lin Chief Business and Strategy Officer James Stanker Chief Financial Officer Non-Employee Directors: Dr. Khalid … of Business at Hood College. Non-Employee Directors Dr. Khalid Islam – Dr. Islam has served as a Director since November 3, 2020. Dr. Islam
S-3
PCSA Processa Pharmaceuticals Inc
1 Apr 21
Shelf registration
8:00pm
(including attorneys’ fees, judgments, fines, Employee Retirement Income Security Act excise taxes or penalties and amounts paid in settlement) reasonably … , employee or agent of ours or who was serving at the request of the Company as a director, officer, employee or agent of another corporation
10-K
2020 FY
PCSA Processa Pharmaceuticals Inc
24 Mar 21
Annual report
8:00pm
and severity of the outbreak, stay-at-home orders, business closures, travel restrictions, supply chain disruptions and employee illness or quarantines, which … plans and strategies develop, we may need to expand the size of our employee and consultant/contractor base. Future growth would impose significant
8-K
EX-10.1
PCSA Processa Pharmaceuticals Inc
18 Feb 21
Processa Pharmaceuticals Announces $10.2 Million Strategic Financing
10:08am
, officers or directors of the Company pursuant to any stock or option plan duly adopted for such purpose, by a majority of the non-employee members … of the Board of Directors or a majority of the members of a committee of non-employee directors established for such purpose for services rendered
8-K
EX-10.3
PCSA Processa Pharmaceuticals Inc
18 Feb 21
Processa Pharmaceuticals Announces $10.2 Million Strategic Financing
10:08am
or equity securities issuable in connection with stock option or other employee benefit plans, the Company shall send to each holder of the Warrants
10-Q
2020 Q3
PCSA Processa Pharmaceuticals Inc
12 Nov 20
Quarterly report
4:01pm
Expenses”), and on the maintenance of employee and compensation levels during a certain time period following the funding of the PPP Loan. We have … payroll, taxes and employee benefits, external consulting and professional fees related to the product testing and our development activities. Non
8-K
PCSA Processa Pharmaceuticals Inc
5 Nov 20
Processa Pharmaceuticals Announces the Appointment of
9:00am
as the Company’s other non-employee directors. On November 3, 2020, Patrick Lin, resigned from the Board of Directors for personal reasons. Mr. Lin’s
8-K
PCSA Processa Pharmaceuticals Inc
13 Oct 20
Processa Pharmaceuticals Announces Appointment of Michael Floyd as Chief Operating Officer
9:30am
discretion. Mr. Floyd is entitled to participate in all employee benefits available to employees of the Company. The Employment Agreement also includes
8-K
EX-10.1
PCSA Processa Pharmaceuticals Inc
13 Oct 20
Processa Pharmaceuticals Announces Appointment of Michael Floyd as Chief Operating Officer
9:30am
of the last signature affixed hereto, by and between Processa Pharmaceuticals Inc., a Delaware corporation (“Processa”), and R. Michael Floyd, (“Employee … acknowledged, Processa and Employee hereby agree as follows: Position of Employment. Processa will employ the Employee in the position of Chief
8-K
EX-1.1
PCSA Processa Pharmaceuticals Inc
6 Oct 20
Processa Pharmaceuticals Announces Pricing of $19.2 Million Public Offering and Uplisting to the Nasdaq Capital Market
4:05pm
subsidiary, any employee benefit plan sponsored by the Company or its subsidiary or any property or assets owned or leased by the Company or its … any officer or director of the Company or its subsidiary, any employee plan sponsored by the Company or its subsidiary or any property or assets owned
424B4
PCSA Processa Pharmaceuticals Inc
5 Oct 20
Prospectus supplement with pricing info
4:16pm
, supply chain disruptions and employee illness or quarantines, which could result in disruptions to our operations and adversely impact our results from … to expand the size of our employee and consultant/contractor base. Future growth would impose significant added responsibilities on members of management
S-1/A
PCSA Processa Pharmaceuticals Inc
30 Sep 20
IPO registration (amended)
4:06pm
, including the duration and severity of the outbreak, stay-at-home orders, business closures, travel restrictions, supply chain disruptions and employee … employees or consultants. As our development and commercialization plans and strategies develop, we may need to expand the size of our employee